Alla studier
RekryteringPHASE2, PHASE3INTERVENTIONELL

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

We're looking into a new medicine called efgartigimod PH20 SC for young people aged 2 to 17 who have a condition affecting their muscles called generalised Myasthenia Gravis (gMG). This study aims to find the most effective and safest dose for children. We'll be giving participants injections of the medicine and closely watching how their bodies react, how much of the medicine is in their system, and if there are any side effects. The main goal is to figure out the right amount of medicine for children with gMG. Those who complete the main study might have the option to continue with the medicine in a follow-up study.

Överblick

Status
Rekrytering
Fas
PHASE2, PHASE3
Sponsor
argenx
Inskrivningsmål
12
Starta
28 jun 2024
Beräknad slutförande
01 sep 2027

Vad handlar denna studie om?

This research is looking at a new treatment called efgartigimod PH20 SC for children and teenagers between 2 and 17 years old who have generalised Myasthenia Gravis (gMG). gMG is a condition that causes muscle weakness. Even though you might already be taking other medicines for your gMG, this study is for those who haven't found enough relief from their current treatments.

The main purpose of this study is to understand how this new medicine works in young people. We want to learn how the body uses and processes the medicine, what effects it has, and importantly, to make sure it's safe and well-tolerated. Finding the right dose for children is really important because medicines can affect children differently than adults.

Over a period of up to 14 weeks, participants will receive the efgartigimod PH20 SC medicine as injections. The research team will regularly check on their health and monitor for any side effects. At the end of these 14 weeks, if the medicine is helping and suitable, some participants might be able to continue receiving the treatment in a longer-term follow-up study, which is called an open-label extension study.

Viktiga punkter

  • This study is for children aged 2-17 with generalised Myasthenia Gravis.
  • It's testing a new injection called efgartigimod PH20 SC.
  • The main goals are to find the right dose and check its safety.
  • Participants will have regular check-ups over 14 weeks.
  • Du kan sluta delta när som helst.
  • Your child will still take their current MG medicines if they are on a stable dose.

Vem kan vara berättigad?

To join this study, a young person must be between 2 and 17 years old. They need to have been diagnosed with generalised Myasthenia Gravis, and doctors must have found specific antibodies in their blood. Also, their current treatments for Myasthenia Gravis shouldn't be working well enough for them, but they need to be on a steady dose of these existing medicines for at least a month before joining.

There are also some things that would mean someone cannot take part. For example, if a young woman could become pregnant, she cannot be pregnant or breastfeeding, and must agree to use effective birth control during the study. Participants cannot have certain other medical conditions or have had particular treatments recently, like some vaccinations, or surgery on their thymus gland in the last three months.

The study also cannot include anyone who has worsening muscle weakness due to an infection or another medicine, or if their Myasthenia Gravis didn't improve after a specific treatment called plasma exchange (PLEX). If they've had cancer, they usually need to have been free of it for at least three years, though some types of skin cancer might be an exception.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är ditt barn mellan 2 och 17 år gammalt?
  2. Does your child have a diagnosis of generalised Myasthenia Gravis confirmed by a blood test?
  3. Are your child's current Myasthenia Gravis medications not fully controlling their symptoms, but they have been on a stable dose for at least a month?
  4. Is your child not currently pregnant, breastfeeding, or planning to become pregnant during the study?
  5. Has your child not had thymus gland surgery in the last 3 months?
  6. Does your child not have new muscle weakness from an infection or other medication?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part, you or your child will be in the study for up to 14 weeks. During this time, they will receive injections of the study medicine, efgartigimod PH20 SC. The research team will arrange for regular check-ups to see how the medicine is affecting your child, track how much of it is in their body, and look for any side effects. This involves visits to the clinic for assessments and monitoring. After the 14 weeks, if suitable, there might be an option to continue the treatment in a follow-up study.

Potentiella risker och fördelar

Taking part in this study could potentially offer your child access to a new treatment that might help with their generalised Myasthenia Gravis, especially if current medicines aren't working well enough. However, like all medicines, there could be side effects or risks that we don't fully know about yet in children. The study team will explain all known risks. Remember, taking part is completely voluntary, and you are free to withdraw from the study at any time without giving a reason, and this won't affect your child's usual medical care.

Platser (22)

  • Carolinas HealthCare System Neurosciences Institute - Neurology
    Verifierat postnummer
    Charlotte, USA· Aktiv men inte rekryterande
  • Centrum för sällsynta neurologiska sjukdomar
    Verifierat postnummer
    Denton, United States· Aktiv men inte rekryterande
  • University of Virginia
    Verifierat postnummer
    Charlottesville, USA· Aktiv men inte rekryterande
  • Royal Children's Hospital Melbourne
    Ungefärlig
    Melbourne, Australien· Rekrytering
  • Sydney Barnsjukhus
    Verifierat postnummer
    Randwick, Australien· Rekrytering
  • UZ Gent
    Verifierat postnummer
    Gent, Belgien· Rekrytering
  • Childrens Hospital of Eastern Ontario
    Verifierat postnummer
    Ottawa, Kanada· Rekrytering
  • Fakultni nemocnice Brno
    Verifierat postnummer
    Brno, Tjeckien· Rekrytering
  • Fakultni nemocnice Ostrava
    Verifierat postnummer
    Ostrava, Tjeckien· Rekrytering
  • AP-HM- Hôpital de La Timone
    Verifierat postnummer
    Marseille, Frankrike· Rekrytering
  • Universitätsklinikum Essen
    Verifierat postnummer
    Essen, Tyskland· Rekrytering
  • Hadassah Medical Center- Ein Kerem
    Verifierat postnummer
    Jerusalem, Israel· Rekrytering

Vanliga frågor

What is generalised Myasthenia Gravis?

It's a condition that causes muscles to become weak and tired, making everyday tasks harder.

What is efgartigimod PH20 SC?

It's a new medicine being tested as an injection for people with generalised Myasthenia Gravis.

Hur länge kommer studien att pågå?

Each participant will be in the main part of the study for up to 14 weeks.

Will my child still take their usual Myasthenia Gravis medicines?

Yes, your child will likely stay on their usual medicines, but these need to be at a stable dose before the study starts.

Kan jag lämna studien när som helst?

Yes, you can choose to withdraw from the study at any point, and it won't affect your child's regular medical care.

Hur du får reda på mer

Sabine Coppieters, MD

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A Study of Efgartigimod PH20 SC in Children Between 2 and Le…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.